DemeRx has reviewed patient data which demonstrate that a single dose of lbogaine is sufficient to detoxify opioid-dependent persons and diminish drug cravings for extended time periods.
DemeRx has evaluated the safety and pharmacokinetics of lbogaine and Noribogaine in normal healthy volunteers and in patients with opioid abuse problems.
We plan to advance lbogaine for opioid detoxification in medically supervised inpatient settings. Noribogaine will be developed as a low dose adjunct therapy for patients in early recovery among other indications.
Our drug products may offer better outcomes for patients suffering from opioid use disorder, including better treatment retention, decreases in illegal opioid use, and a decrease in risky behaviors related to HIV and hepatitis C.
Key Team
Richard Serbin, Executive Chairman BoD
Global strategy advisor and entrepreneur with credentials both in pharmacy and law, 40 years of service as an FDA regulatory and patent attorney in the healthcare industry.
Deborah Mash, PhD Chief Executive Officer & Founder
Neuroscientist, inventor and entrepreneur with over 25 years of experience in the field of addiction biology and small molecule development.
Michael Karukin PhD, Chief Operating Officer
Twenty years of experience in the pharmaceutical industry, clinical trial management, patient registries and FDA REMS monitoring.
Pascal J. Goldschmidt MD, FACC, FAHA, Chief Medical Officer
An accomplished physician (cardiologist), professor, healthcare leader, NIH-funded medical researcher and inventor.
John Thomas CPA, Chief Financial Officer
Decades of experience in senior management in biotech and healthcare fields.
Interested in more information?
Learn about our two leading drug candidates to dominate the $1.9B opioid addiction market.